SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Andreas Varkaris, Anastasia D. Katsiampoura, John C. Araujo, Gary E. Gallick, Paul G. Corn, Src signaling pathways in prostate cancer, Cancer and Metastasis Reviews, 2014, 33, 2-3, 595

    CrossRef

  2. 2
    Sarah E. Fenton, Kelli A. Hutchens, Mitchell F. Denning, Targeting Fyn in Ras-transformed cells induces F-actin to promote adherens junction-mediated cell–cell adhesion, Molecular Carcinogenesis, 2014, 53, 9
  3. 3
    Emmanuel S. Antonarakis, Elisabeth I. Heath, Edwin M. Posadas, Evan Y. Yu, Michael R. Harrison, Justine Y. Bruce, Steve Y. Cho, Gregory E. Wilding, Gerald J. Fetterly, David G. Hangauer, Min-Fun R. Kwan, Lyn M. Dyster, Michael A. Carducci, A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer, Cancer Chemotherapy and Pharmacology, 2013, 71, 4, 883

    CrossRef

  4. 4
    Akshata R Udyavar, Megan D Hoeksema, Jonathan E Clark, Yong Zou, Zuojian Tang, Zhiguo Li, Ming Li, Heidi Chen, Alexander Statnikov, Yu Shyr, Daniel C Liebler, John Field, Rosana Eisenberg, Lourdes Estrada, Pierre P Massion, Vito Quaranta, Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer, BMC Systems Biology, 2013, 7, Suppl 5, S1

    CrossRef

  5. 5
    Giulio Poli, Tiziano Tuccinardi, Flavio Rizzolio, Isabella Caligiuri, Lorenzo Botta, Carlotta Granchi, Gabriella Ortore, Filippo Minutolo, Silvia Schenone, Adriano Martinelli, Identification of New Fyn Kinase Inhibitors Using a FLAP-Based Approach, Journal of Chemical Information and Modeling, 2013, 53, 10, 2538

    CrossRef

  6. 6
    J G van Oosterwijk, M A J H van Ruler, I H Briaire-de Bruijn, B Herpers, H Gelderblom, B van de Water, J V M G Bovée, Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells, British Journal of Cancer, 2013, 109, 5, 1214

    CrossRef

  7. You have free access to this content7
    John C. Araujo, Paul Mathew, Andrew J. Armstrong, Edward L. Braud, Edwin Posadas, Mathew Lonberg, Gary E. Gallick, Géralyn C. Trudel, Prashni Paliwal, Shruti Agrawal, Christopher J. Logothetis, Dasatinib combined with docetaxel for castration-resistant prostate cancer, Cancer, 2012, 118, 1
  8. 8
    H. Cai, D. A. Smith, S. Memarzadeh, C. A. Lowell, J. A. Cooper, O. N. Witte, Differential transformation capacity of Src family kinases during the initiation of prostate cancer, Proceedings of the National Academy of Sciences, 2011, 108, 16, 6579

    CrossRef

  9. 9
    Vipin Yadav, Mitchell F. Denning, Fyn is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration, Molecular Carcinogenesis, 2011, 50, 5
  10. 10
    John Araujo, Christopher Logothetis, Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors, Cancer Treatment Reviews, 2010, 36, 6, 492

    CrossRef

  11. 11
    Yoshihito D. Saito, Ana R. Jensen, Ravi Salgia, Edwin M. Posadas, Fyn, Cancer, 2010, 116, 7
  12. 12
    Fred Saad, Allan Lipton, SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer, Cancer Treatment Reviews, 2010, 36, 2, 177

    CrossRef